We’re Hiring! View Open Positions


ALTA-2530 as a treatment for BOS and Chemical Lung Injury

ALTA-2530 is a novel inhaled formulation of recombinant and anti-inflammatory IL-1 receptor antagonist (IL-1Ra) in development for bronchiolitis obliterans syndrome (BOS) and chemical lung injury. It is the only inhaled IL-1Ra being developed to treat respiratory conditions.

As an inhaled medication, ALTA-2530 can be delivered directly to the lungs to achieve higher levels of IL-1Ra in bronchioles than are feasible with systemic administration. The U.S. FDA granted ALTA-2530 orphan status for BOS under the Orphan Drug Designation program.

In addition, we have partnered with the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. Department of Health and Human Services (HHS) to investigate the utility of ALTA-2530 for the treatment of acute and chronic chemical lung injuries caused by the inhalation of sulfur mustard.

Learn more about the diseases we are evaluating ALTA-2530 in BOS and chemical lung injury

Learn more about our scientific approach with ALTA-2530 here

Contact us for more information